As we have all witnessed over the past several months in the general news media, there is plenty of "fake" news. Although Mako may be correct that CTIX did raise cash from Platinum in the early forming of the company history prior to access to Aspire funding, there is certainly no evidence of fraud by Cellceutix itself. This is another attempt on Mako part to rattle shareholders by misleading information. I personally am holding very strong, the clinical trials are all progressing and I am eagerly awaiting trial results. To have 3 drugs in active clinical trials with multiple indications - is an extremely favorable risk/reward valuation. Moreover, with the CTIX teams focus on partnership in the near future, I am confident that we may likely see a return of many multiples on our initial investments (even for those that may have bought at the peak). Stay LONG and STRONG!
News 
Market Data 
Discover 
